title: Treatment of dry age-related macular degeneration.
abstract: A number of different approaches are under development for treating nonexudative manifestations of age-related macular degeneration (AMD). Some interventions target specific pathways that are believed to play a role in AMD pathogenesis, e.g. oxidative damage, lipofuscin accumulation, chronic inflammation (including complement activation), extracellular matrix changes (e.g. β-amyloid accumulation), impaired choroidal blood flow, and apoptosis. In principle, these therapies can be combined ('combination therapy'), which may lead to synergistic effects that include better visual outcome, less likelihood for 'escape' (i.e. drug resistance), and less frequent treatment.
authors.affiliation: Department of Ophthalmology, University of Paris Est Créteil, Centre Hospitalier Intercommunal de Créteil, Créteil, France.
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Querques
authors.forename: Philip J
authors.initials: PJ
authors.lastname: Rosenfeld
authors.forename: Edoardo
authors.initials: E
authors.lastname: Cavallero
authors.forename: Enrico
authors.initials: E
authors.lastname: Borrelli
authors.forename: Federico
authors.initials: F
authors.lastname: Corvi
authors.forename: Lea
authors.initials: L
authors.lastname: Querques
authors.forename: Francesco M
authors.initials: FM
authors.lastname: Bandello
authors.forename: Marco A
authors.initials: MA
authors.lastname: Zarbin
mesh_terms: D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000975:Antioxidants / Q000627:therapeutic use*; D057092:Geographic Atrophy / Q000188:drug therapy*; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D008062:Lipofuscin / Q000037:antagonists & inhibitors*; D033581:Stem Cell Transplantation
chemical_list: D000893:Anti-Inflammatory Agents; D000975:Antioxidants; D005938:Glucocorticoids; D008062:Lipofuscin